Clinical Trial Update: Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial investigating pramlintide for weight reduction in schizophrenia-related weight gain; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• pramlintide (pramlintide)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED | Results posted: 2018-11-16